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Open Forum Infectious Diseases
MAJOR ARTICLE

Incidence and Severity of Drug Interactions Before and
After Switching Antiretroviral Therapy to Bictegravir/
Emtricitabine/Tenofovir Alafenamide in TreatmentExperienced Patients
Jason J. Schafer,1 Neha S. Pandit,2 Agnes Cha,3,a Emily Huesgen,4 Melissa Badowski,5 Elizabeth M. Sherman,6,7 Jennifer Cocohoba,8 Ayako Shimada,9 and
Scott W. Keith9
1
Department of Pharmacy Practice, Jefferson College of Pharmacy, Thomas Jefferson University, Philadelphia, Pennsylvania, USA, 2Department of Pharmacy Practice and Science, University
of Maryland Baltimore School of Pharmacy, Baltimore, Maryland, USA, 3Brooklyn Hospital Center, Brooklyn, New York, USA, 4Department of Pharmacy Practice, Indiana University Health,
Indianapolis, Indianapolis, USA, 5Section of Infectious Diseases Pharmacotherapy, Department of Pharmacy Practice, University of Illinois at Chicago, College of Pharmacy, Chicago, Illinois, USA,
6
Department of Pharmacy Practice, College of Pharmacy, Nova Southeastern University, Fort Lauderdale, Florida, USA, 7Division of Infectious Diseases, Memorial Healthcare System, Hollywood,
Florida, USA, 8Department of Clinical Pharmacy, University of California San Francisco School of Pharmacy, San Francisco, California, USA, and 9Division of Biostatistics, Sidney Kimmel Medical
College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA

Background.   Switching antiretroviral therapy (ART) in people with HIV (PWH) can influence their risk for drug–drug interactions (DDIs). The purpose of this study was to assess changes in the incidence and severity of DDIs among PWH who switched
their ART to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF).
Methods.   This was a multicenter retrospective cohort study of PWH on ART and at least 1 concomitant medication (CM)
who switched to BIC/FTC/TAF between 3/2018 and 6/2019. Using the University of Liverpool’s HIV Drug Interaction Database, 2
DDI analyses were performed for each patient. The first assessed patients’ preswitch ART regimens with their CM list. The second
assessed the same CM list with BIC/FTC/TAF. Each ART-CM combination was given a score of 0 (no or potential weak interaction),
1 (potential interaction), or 2 (contraindicated interaction). A paired t test analyzed changes in total DDI scores following ART
switches, and linear regression examined factors contributing to DDI score reductions.
Results.   Among 411 patients, 236 (57%) had at least 1 DDI present at baseline. On average, baseline DDI scores (SD) were 1.4
(1.8) and decreased by 1 point (95% CI, –1.1 to –0.8) after patients switched to BIC/FTC/TAF (P < .0001). After adjusting for demographics, baseline ART, and CM categories, switching to BIC/FTC/TAF led to significant DDI score reductions in patients receiving
CMs for cardiovascular disease, neurologic/psychiatric disorders, chronic pain, inflammation, gastrointestinal/urologic conditions,
and conditions requiring hormonal therapy.
Conclusions.   Treatment-experienced PWH eligible to switch their ART may experience significant declines in number and
severity of DDIs if switched to BIC/FTC/TAF.
Keywords.
ART; bictegravir; drug interactions; HIV; switch.
People with HIV (PWH) often have or develop other chronic
medical conditions as they age and receive multiple medications in addition to their antiretroviral therapy (ART) [1]. This
increases their risk for polypharmacy and its complications,
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including medication nonadherence, HIV treatment failure,
adverse drug events, and drug–drug interactions (DDIs) [2–6].
In virally suppressed treatment-experienced PWH, switching
ART can simplify treatment, improve tolerability, and limit
long-term toxicity. It can also influence the presence of DDIs in
those receiving concomitant medications (CMs) [7–9].
Given their efficacy, safety, and tolerability, integrase inhibitor–based regimens are preferred therapy options and are commonly used to simplify ART in treatment-experienced patients
[9–11]. Among the integrase inhibitors, bictegravir has few
DDIs and is available in a single-tablet regimen with tenofovir
alafenamide and emtricitabine (BIC/FTC/TAF) [12]. The extent to which switching ART to BIC/FTC/TAF can influence
the presence of DDIs in treatment-experienced PWH is unclear.
The purpose of this study was to assess changes in the incidence
and severity of DDIs after switching to BIC/FTC/TAF.
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METHODS

This was a multicenter retrospective cohort study of adult
PWH on ART and at least 1 CM who switched to BIC/FTC/
TAF between 3/2018 and 6/2019 in the outpatient setting.
Demographic data including age, sex, and race were extracted
from medical records of eligible patients, along with their
medications, duration of HIV infection, duration of ART,
number of previous ART regimens, preswitch HIV RNA, and
their reason for switching to BIC/FTC/TAF. Institutional review board approval was obtained before data collection at
each study center.
To assess the incidence and severity of DDIs with CMs before
and after each patient’s switch to BIC/FTC/TAF, the University
of Liverpool’s HIV Drug Interaction Database was used [13].
Two DDI analyses were performed for each patient. The first assessed a patient’s preswitch ART regimen with the list of active
medications located in their electronic medical record on the
day they switched their ART. The second assessed the same CM
list with BIC/FTC/TAF. Each ART-CM combination was given
a numerical score that corresponded to the DDI categories
listed in the University of Liverpool database. These were scores
of 0 (no or potential weak interaction), 1 (potential interaction),
or 2 (contraindicated interaction). Total DDI scores for each
patient, both before and after switching to BIC/FTC/TAF, were
then calculated.
A paired t test was used to analyze changes in DDI scores
following ART switches, and a linear regression model was
used to examine factors contributing to DDI score reductions.
In addition, McNemar’s test was used to analyze changes in
the proportion of patients with at least 1 DDI before and after
switching to BIC/FTC/TAF. Covariates in the regression model
included patient demographics, viral suppression status, and
baseline ART. To analyze the influence of CMs in the regression

model, each medication was placed into 1 of the following
categories according to its therapeutic indication: cardiovascular, antihyperglycemic, anti-inflammatory, anti-infective,
chronic pain, neurologic/psychiatric, gastrointestinal/urologic,
hormonal therapy, or polyvalent supplements (Table 1). All statistical analyses were performed with SAS 9.4 (SAS Institute
Inc., Cary, NC, USA) at a significance level of .05.

RESULTS

A total of 411 patients met study criteria and were included in
the analysis (Table 2). The majority were African American
(70.6%) and male (61.6%), with a mean age of 51 years. Patients
had been living with HIV and receiving ART for a median of
14 and 10 years, respectively. The majority were receiving regimens containing either dolutegravir (37%) or elvitegravir
(29.4%) plus 2 nucleoside reverse transcriptase inhibitors before
switching to BIC/FTC/TAF. Most were also receiving at least 5
CMs (56.9%). The most common baseline NRTI combinations
were tenofovir disoproxil fumarate or TAF plus FTC (72%) and
abacavir plus lamivudine (26%). The most commonly documented reasons for switching to BIC/FTC/TAF were to improve
long-term safety (23.6%), reduce regimen complexity (16.8%),
and mitigate DDIs (14.1%).
Of the 411 patients analyzed, 236 (57%) had at least 1 of the
552 DDIs identified at baseline. The majority of baseline DDIs
had scores of 1 (497/552, 90%). Those with scores of 2 (55/552,
10%) were most commonly the result of pharmacokinetic
“boosting” agents combined with either corticosteroids (30/55,
54.5%), quetiapine (7/55, 12.7%), clopidogrel (5/55, 9.1%), or
direct oral anticoagulants (3/55, 5.5%). Rilpivirine used in combination with proton pump inhibitors (7/55, 12.7%) was also
common. After switching to BIC/FTC/TAF, only 136/411 (33%)

Table 1.   Concomitant Medications of Study Participants and Their Corresponding Categories
Cardiovascular

Apixaban, amiodarone, amlodipine, atenolol, atorvastatin, clopidogrel, diltiazem, digoxin, eltrombopag,
hydralazine, metoprolol, nifedipine, pravastatin, rivaroxaban, rosuvastatin, simvastatin, sotolol,
vorapaxar, valsartan, verapamil, warfarin

Antihyperglycemic

Glipizide, metformin, liraglutide, sitagliptin

Anti-inflammatory

Aspirin, budesonide (inhaled/nasal), celecoxib, ciclesonide (nasal), dexamethasone (systemic), diclofenac,
fluticasone (inhaled/nasal), hydrocortisone oral, ibuprofen, meloxicam, mometasone (inhaled/nasal),
methylprednisolone (injections), naproxen, prednisone (systemic), triamcinolone (inhaled/nasal)

Chronic pain

Fentanyl, hydrocodone, morphine, lidocaine, oxycodone, tizanidine

Anti-infective

Acyclovir, atovaquone, clindamycin, doxycycline, fluconazole, itraconazole, ketoconazole, trimethoprim/
sulfamethoxazole, voriconazole, valacyclovir

Hormonal therapy

Calcifediol, cholecalciferol, estradiol injection, ethinyl estradiol (oral), ethinyl estradiol/norelgestromin
(transdermal), norgestimate (oral), levothyroxine, testosterone

Neurologic/psychiatric

Alprazolam, amitriptyline, aripiprazole, bupropion, buspirone, clonazepam, diazepam, divalproex,
escitalopram, fluoxetine, lurasidone, mirtazapine, nortriptyline, paroxetine, phenytoin, quetiapine,
risperidone, sertraline, topiramate, trazodone, valproic acid, zolpidem

Gastrointestinal/urologic

Alfuzosin, antacids, finasteride, loperamide, omeprazole, pantoprazole, ranitidine, sildenafil, tamsulosin,
tadalafil

Polyvalent cation supplements

Multivitamins, calcium supplements, iron supplements

Other

Hydroxyzine, methamphetamine, salmeterol
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Table 2.   Descriptive Summary of Baseline Characteristics (n = 411)
All (n = 411)
Site, No. (%)

University of Maryland, Baltimore
Thomas Jefferson University Hospital

95 (23.1)

The Brooklyn Hospital

61 (14.8)

Indiana University LifeCare

60 (14.6)

University of Illinois at Chicago

40 (9.7)

Memorial Healthcare System

35 (8.5)

University of California, San Francisco
Age, mean (SD)
Gender, No. (%)

Male

253 (61.6)

Female

151 (36.7)
7 (1.7)

Black/African American

75 (18.2)

Hispanic/Latinx

36 (8.8)
8 (1.9)

Native Hawaiian/Other Pacific Islander
No. of years with HIV diagnosis, median (Q1, Q3)a

Switch reason, No. (%)e

10.0 (6.0, 15.0)
1–3

214 (52.1)

4–6

60 (14.6)

≥7

11 (2.7)

Yes

324 (78.8)

No

52 (12.7)

Long-term safety

97 (23.6)

Complexity

69 (16.8)

Other

66 (16.1)

Drug interactions

58 (14.1)

Side effects

45 (10.9)

Not documented

36 (8.8)

Toxicity

14 (3.4)

Virologic failure
Polypharmacy (≥5 concomitant medications), No. (%)

5 (1.2)

Cost

2 (0.5)

Yes

234 (56.9)

No

177 (43.1)

No. of concomitant medications, median (Q1, Q3)
No. of concomitant medications, No. (%)

5.0 (3.0, 9.0)
0

7 (1.7)

1–4

172 (41.8)

5–9

141 (34.3)

10–14

66 (16.1)

15–19

16 (3.9)

≥20
Baseline ART regimen, No. (%)

2 (0.5)
14.0 (8.0, 22.0)

Total No. of years on ART, median (Q1, Q3)b

Viral suppression (HIV RNA <200 copies/mL), No. (%)d

290 (70.6)

White
Asian

No. of previous ART regimens, No. (%)c

20 (4.9)
51.3 (12.4)

Transgender female
Race, No. (%)

100 (24.3)

9 (2.2)

Dolutegravir plus 2 NRTIs

152 (37)

Elvitegravir/cobicistat plus 2 NRTIs

121 (29.4)

Boosted PI plus 2 NRTIs

59 (14.4)

Efavirenz plus 2 NRTIs

34 (8.3)

Rilpivirine plus 2 NRTIs

29 (7.1)

Nevirapine plus 2 NRTIs

4 (1.0)

Dolutegravir plus a boosted PI and 2 NRTIs

4 (1.0)

Dolutegravir plus rilpivirine

3 (0.7)

Elvitegravir/cobicistat plus a PI and 2 NRTIs

2 (0.5)

3 NRTIs

2 (0.5)

Etravirine plus a boosted PI and 2 NRTIs

1 (0.2)

Abbreviations: ART, antiretroviral therapy; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.
a

Data not available for 51 subjects.

b

Data not available for 144 subjects.

c

Data not available for 126 subjects.

d

Data not available for 35 subjects.

e

Data not available for 19 subjects.
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Figure 1.
Subjects with at least 1 DDI between their ART and selected CM categories pre- and postswitch. Abbreviations: ART, antiretroviral therapy; CM, concomitant
medication; DDI, drug–drug interaction; GI, gastrointestinal.

patients continued to have at least 1 DDI (P < .0001). Declines
in DDIs were observed for nearly all CM categories (Figure 1).
The total number of DDIs declined to 188, almost all of which
had a score of 1 (187/188, 99.5%); these were most commonly
the result of BIC/FTC/TAF used in combination with either
polyvalent cation supplements (125/188, 66.5%) or metformin
(45/188, 23.9%).
In terms of total DDI scores, patients had a median score (interquartile range) of 1 (0–2) or an average (SD) of 1.4 (1.8) at
baseline and experienced a 1-point reduction (95% CI, –1.1 to
–0.8) after switching to BIC/FTC/TAF (P < .0001). In the regression model, DDI score reductions were not associated with

patient demographics, viral suppression status, or baseline ART,
but were significantly associated with patient CMs (Table 3). For
instance, patients receiving cardiovascular medications experienced an average DDI score reduction of 1.42 (95% CI, –1.64
to –1.19; P < .0001) after switching to BIC/FTC/TAF. Similar
score reductions were associated with neurologic/psychiatric
medications, gastrointestinal/urologic medications, hormonal
therapies, and medications for chronic pain. The largest score
reductions were associated with anti-inflammatory medications
(–1.9; 95% CI, –2.14 to –1.65; P < .0001). The only CMs that
were not associated with DDI score reductions were polyvalent
cation supplements and medications for diabetes.

Table 3.   Linear Regression for the Difference of DI Scores (Post–Pre; n = 376a)
Variable

Estimate

95% CI

P Value

Intercept (ref: age 51 y and Black/AA)

0.38

(0.01 to 0.75)

.05

Age (per year)

0.00

(0.00 to 0.01)

.13

–0.17

(–0.36 to 0.02)

.08

0.05

(–0.18 to 0.29)

.66

Viral suppression (yes)

–0.17

(–0.38 to 0.04)

.11

Dolutegravir-based ART (yes)

–0.18

(–0.50 to 0.15)

.28

Elvitegravir-based ART (yes)

0.00

(–0.34 to 0.34)

.00

NNRTI-based ART (yes)

0.23

(–0.11 to 0.57)

.19

PI-based ART (yes)

–0.03

(–0.37 to 0.32)

.89

Interactions between the patient’s ART and cardiovascular medications at baseline (yes)

–1.42

(–1.64 to –1.19)

<.0001

White
Other race (Hispanic/Latino, Asian, Native Hawaiian/other Pacific Islander)

Interactions between the patient’s ART and hyperglycemic medications at baseline (yes)

0.02

(–0.23 to 0.28)

.85

Interactions between the patient’s ART and anti-inflammatory medications at baseline (yes)

–1.90

(–2.14 to –1.65)

<.0001

Interactions between the patient’s ART and pain medications at baseline (yes)

–1.49

(–1.85 to –1.13)

<.0001

Interactions between the patient’s ART and anti-infectives at baseline (yes)

–1.05

(–1.38 to –0.72)

<.0001

Interactions between the patient’s ART and hormonal therapies at baseline (yes)

–0.82

(–1.16 to –0.48)

<.0001

Interactions between the patient’s ART and neurologic and psychiatric medications at baseline (yes)

–1.52

(–1.72 to –1.32)

<.0001

Interactions between the patient’s ART and gastrointestinal and urologic medications at baseline (yes)

–1.51

(–1.79 to –1.24)

<.0001

Interactions between the patient’s ART and polyvalent supplements at baseline (yes)

–0.02

(–0.21 to 0.17)

.82

Interactions between the patient’s ART and other medications at baseline (yes)

–0.86

(–1.27 to –0.45)

<.0001

Abbreviations: ART, antiretroviral therapy; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.
P < .05 is considered significant.
a

This analysis was performed for all patients who had evidence of their viral suppression status (yes or no) at the time of their ART switch.
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DISCUSSION

We observed significant declines in the incidence and severity of DDIs among treatment-experienced PWH who
switched their ART to BIC/FTC/TAF. Importantly, these
declines were significantly associated with a patient’s CMs
rather than their demographics, viral suppression status,
or baseline ART. DDI declines also occurred among CMs
representing a broad range of comorbid conditions. This is
important because PWH have a disproportionate risk for
developing multiple medical conditions, experiencing polypharmacy, and incurring DDIs [1–6, 14].
The majority of subjects in this study were experiencing
polypharmacy and receiving CMs for conditions common to
patients aging with HIV [15]. These included cardiovascular
disease, chronic pain, gastrointestinal diseases, and urologic
disorders. Consistent with prior studies, CMs for these conditions were common sources of DDIs for patients at baseline in
our study [14, 16, 17]. DDI declines were associated with CMs
in these medication categories when patients switched to BIC/
FTC/TAF. These DDI declines might have been more substantial in an elderly patient population, because as age progresses,
polypharmacy and drug interactions among PWH increase substantially [14]. In addition, patients in this study were also frequently receiving CMs for conditions common to all PWH such
as neurologic disease, psychiatric illness, co-infections, and conditions requiring hormonal therapy. When patients switched to
BIC/FTC/TAF, DDI declines were also associated with CMs in
these medication categories. The only CM categories not associated with DDI declines were diabetes and polyvalent cation
supplements. This finding may have been expected, as most
subjects were on dolutegravir or elvitegravir at baseline, which
also interact with metformin and supplements containing polyvalent cations. Overall, these findings suggest that if patients are
able to switch their ART to BIC/FTC/TAF, they may experience
significant declines in DDIs when they are also receiving CMs
for medical conditions common to all PWH.
In terms of DDI severity, corticosteroids were the most
common source of contraindicated DDIs for patients at baseline. These interactions were the result of corticosteroids used
in combination with pharmacokinetic boosting agents such
as ritonavir and cobicistat. Pharmacokinetic boosting agents
are strong cytochrome P450 inhibitors that can elevate corticosteroid concentrations, leading to adrenal suppression and
Cushing’s syndrome [18]. Boosting agents also led to contraindicated DDIs in this study with certain antithrombotic and
antipsychotic medications by inhibiting their cytochrome P450
metabolism. In prior studies, these types of contraindicated
interactions increased a person’s risk for experiencing significant toxicity requiring hospitalization [19, 20]. Because BIC/
FTC/TAF is an unboosted regimen, switching not only reduced
the total number of DDIs for patients in this study, but also

removed nearly all contraindicated DDIs that may otherwise
have resulted in patient harm.
The low incidence of contraindicated DDIs with BIC/FTC/
TAF was also recently demonstrated in a study of nearly 5000
German PWH [21]. Investigators in this study also utilized the
University of Liverpool Drug Interaction Database to evaluate
potential DDIs among patients receiving BIC/FTC/TAF and at
least 1 CM. Overall, the incidence of DDIs was low, with several common medication classes posing no risk for DDIs with
BIC/FTC/TAF including anti-ulcerants, antirheumatics, and
lipid-lowering agents. Similar to our study, contraindicated
combinations with BIC/FTC/TAF in the German cohort were
rare (<0.25%) and the result of metabolism-inducing medicines such as carbamazepine, oxcarbazepine, and rifampicin
in the German cohort and phenytoin in our analysis. Overall,
both studies demonstrate that there is a low potential for DDIs
between BIC/FTC/TAF and CMs including contraindicated
combinations. Unique to our study, however, is the finding
that a substantial number of DDIs can be avoided and contraindicated combinations can be nearly eliminated if treatmentexperienced patients can switch their ART to BIC/FTC/TAF
from their current regimen.
Current treatment guidelines recommend switching a
patient’s ART regimen when feasible in order to mitigate DDIs,
as well as reduce treatment complexity, improve tolerability,
limit long-term toxicity, and reduce costs [7–9]. However, it
should be noted that switching ART can also lead to new adverse events and even virologic breakthrough in treatmentexperienced patients. Furthermore, switching to or from a
boosted ART regimen may require dosing adjustments for a
patient’s CMs. Some subjects in this study were switched to mitigate DDIs; however, the majority switched for other reasons
including safety, tolerability, and regimen simplification. While
prior studies have demonstrated that regimen simplification
can reduce a patient’s risk for DDIs, the results of this study suggest that DDI reductions may occur regardless of the reasons for
switching a patient’s regimen [22].
This study has several limitations. First, our analysis only included patients who switched to BIC/FTC/TAF. However, it
should be noted that BIC and dolutegravir have nearly identical
drug interaction profiles, and similar DDI reductions would have
occurred if patients in this study had switched their baseline regimens to dolutegravir/FTC/TAF. Moreover, there are specific
DDI situations when a dolutegravir-based regimen may be preferred to BIC/FTC/TAF (ie, concomitant rifamycins) that were
not captured in this study. Second, our assessment of DDIs using
the University of Liverpool’s HIV Drug Interaction Database is
only reflective of the study’s time period. Changes in the tool’s
identification and assessment of DDI severity since this study
was conducted are possible. Furthermore, the clinical relevance
of each DDI identified in this study was not evaluated by the

Drug interactions before and after bictegravir • ofid • 5

investigators, and it is possible that separate DDIs with the same
scores could differ considerably in their clinical relevance. Also,
as a retrospective cohort study, we relied on the accuracy and
completeness of medical records, but omissions or inaccuracies
could have influenced the results. For example, we were unable to
collect patients’ nonprescription medications consistently, which
may have resulted in an underestimation of DDIs. We were also
unable to assess patient adherence to CMs, which may have resulted in an overestimation of DDIs. We also placed CMs into
groups for our analysis, which limited our ability to investigate
DDI changes for individual CMs following switches to BIC/FTC/
TAF. In addition, dosing adjustments made to offset DDIs were
not considered within our analysis. Lastly, our cohort was predominantly African American and male from large, academic,
and urban medical centers in the United States. As a result, the
findings may not be generalizable to patients living in rural settings or those living outside of the United States.
CONCLUSIONS

Treatment-experienced PWH who are receiving CMs and are
eligible to switch their ART may experience significant declines
in the number and severity of DDIs if their regimen is switched
to BIC/FTC/TAF. This may be particularly important for patients experiencing polypharmacy and those receiving CMs for
conditions common to patients aging with HIV.
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